Prevalence of aPL in SP-APS and SN-APS.
| aPL | SP-APS | SN-APS | |||
|---|---|---|---|---|---|
| n = 107 | % | n = 68 | % | ||
| aCL | IgG | 33 | 30.8 | 1 | 1.5 |
| IgM | 20 | 18.7 | 1 | 1.5 | |
| IgA | 10 | 9.3 | 0 | 0.0 | |
| Anti-β2-GPI | IgG | 28 | 26.2 | 0 | 0.0 |
| IgM | 25 | 23.4 | 1 | 1.5 | |
| IgA | 24 | 22.4 | 1 | 1.5 | |
| Anti-β2-GPI DI | IgG | 29 | 27.1 | 0 | 0.0 |
| aPS | IgG | 46 | 43.0 | 3 | 4.4 |
| IgM | 13 | 12.1 | 1 | 1.5 | |
| IgA | 3 | 2.8 | 0 | 0.0 | |
| aPS/PT | IgG | 44 | 41.1 | 4 | 5.9 |
| IgM | 38 | 35.5 | 4 | 5.9 | |
| aPE | IgG | 25 | 23.4 | 8 | 11.8 |
| IgM | 27 | 25.2 | 1 | 1.5 | |
| aCL/Vim | IgG | 48 | 44.8 | 11 | 16.2 |
Single reactivity against noncriteria marker was seen in 19/25 aPL positive SN-APS samples (3 IgG and 3 IgM aPS/PT, 1 IgG aPS, 5 IgG aPE, and 7 IgG aCL/Vim). aPL: antiphospholipid antibodies; APS: antiphospholipid syndrome; SP-APS: seropositive APS; SN-APS: seronegative APS; aCL: anticardiolipin antibodies; anti-β2-GPI: anti-β2-glycoprotein I; DI: Domain-I; aPE: antibodies to phosphatidylethanolamine; aCL/Vim: anticardiolipin/vimentin antibodies; aPS/PT: antiphosphatidylserine/prothrombin antibodies; aPS: antibodies to phosphatidylserine.